Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial Eli Lilly and Company and Merck announced another immuno-oncology collaboration that will evaluate abemaciclib, Lilly’s cyclin-dependent kinase 4 and 6 inhibitor, and Merck’s KEYTRUDA® in a Phase I study across multiple tumor types. [Eli Lilly and Company] Press Release ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumor Consortium for ICT-107 Phase III Registrational Trial in Glioblastoma ImmunoCellular Therapeutics, Ltd. announced the establishment of an agreement with The Canadian Brain Tumour Consortium for the Phase III registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma. [ImmunoCellular Therapeutics, Ltd.] Press Release Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy Bellicum Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Agensys, Inc., an affiliate of Astellas, and Bellicum have entered into a global license agreement, granting Bellicum rights to develop and commercialize adoptive cell therapies, including CAR-T cells, for tumors expressing prostate stem cell antigen (PSCA) using PSCA technology, both in-licensed and developed at Agensys. [Bellicum Pharmaceuticals, Inc.] Press Release Prima BioMed Progresses Japanese Collaboration Prima BioMed Ltd. announced important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. Prima’s IMP321 Antigen Presenting Cell activator is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University. [Prima BioMed Ltd.] Press Release Complix Advances Novel Biospecific Immunotherapeutic CMX-02 – Enters Agreement with Selexis to Access SUREtechnology Platform™ Complix NV announced that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease. CMX-02 is a bispecific Alphabody-antibody fusion protein that simultaneously targets TNFα and IL-23. [Complix NV] Press Release Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-Esophageal Junction Cancers Merck KGaA and Pfizer announced the initiation of two Phase III studies of avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction cancers, which are aggressive cancers with poor survival rates. [Pfizer Inc.] Press Release U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune’s TPIV 200 in the Treatment of Ovarian Cancer TapImmune, Inc. announced that it has received Orphan Drug Designation from the U.S. Food & Drug Administration’s Office of Orphan Products Development for its cancer vaccine TPIV 200 in the treatment of ovarian cancer. [TapImmune, Inc.] Press Release FDA Grants Roche’s Alecensa (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer Roche announced that the US Food and Drug Administration (FDA) granted accelerated approval to Alecensa® for the treatment of people with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. [F. Hoffmann-La Roche Ltd.] Press Release Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer Advaxis, Inc. announced that the European Medicines Agency has granted Orphan Drug Designation to axalimogene filolisbac for the treatment of anal cancer. [Advaxis, Inc.] Press Release |